获得性囊性病亚型肾细胞癌(ACD-RCC):单机构患病率与影像特征
回顾性分析2016至2021年间107例因可疑肾肿块行全肾切除术的获得性囊性肾病(ACKD)患者,共122例次手术、148个肿块;ACD-RCC为第三常见肿瘤(21个),CT上多为实性、增强不定或轻度强化,MRI常见T2低信号和弥散受限,无单一影像特征可确诊。
要点
- ACKD患者中ACD-RCC为第三常见肾肿瘤(21/148个肿块)。
- ACD-RCC在CT上多为实性,增强多表现为不定或轻度强化。
- MRI上T2低信号和弥散受限为ACD-RCC最常见特征。
核心结论
- ACD-RCC是ACKD患者中第三常见的肾肿瘤,无单一影像特征可确诊,但通常为实性肿块,CT上多数表现为增强不定或轻度强化,MRI最常见特征为T2低信号和弥散受限。
研究设计与样本
- 回顾性研究,纳入2016至2021年间107例ACKD患者因可疑肾肿块行全肾切除术的122例次手术,共识别148个肿块,以病理报告为参考标准。
关键影像表现/征象
- 21例ACD-RCC中16例有术前影像:10个为实性/大部分实性,6个为囊实性混合。
- 平扫CT平均衰减为35 HU(范围13-52)。
- 多期CT中1个无强化、3个强化不定、3个有强化。
- MRI检查的4个肿瘤均显示T2低信号和弥散受限。
- CEUS检查的5个肿块均显示强化。
诊断标准与关键数值
- CT强化标准:无强化为强化差值<10 HU,强化不定为10-20 HU,有强化为>20 HU。
临床应用与阅片要点
- ACKD患者肾脏肿块鉴别诊断应包括ACD-RCC,其为第三常见肿瘤。
- ACD-RCC在CT上可表现为强化不定或轻度强化,不应仅据此排除恶性。
- MRI上T2低信号和弥散受限可见于ACD-RCC,但无单一影像特征可确诊。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Acquired cystic kidney disease (ACKD) is commonly seen in patients with end-stage renal disease (ESRD), and patients with ACKD have an increased risk of renal cell carcinoma (RCC). Acquired cystic disease-associated RCC (ACD-RCC) was incorporated into the 2016 World Health Organization Classification. This study aims to describe the imaging features of ACD-RCC, which are not well reported previously.
METHODS: Retrospective review of patients with ACKD who underwent total nephrectomy for concern of a renal mass between 2016 and 2021 yielded 122 nephrectomies in 107 patients. Pathology reports were searched for type and subtype of mass. In ACD-RCC subtypes, imaging studies were evaluated for modality and contrast enhancement (CE). Imaging findings assessed included cystic/solid nature, unenhanced CT (NECT) attenuation, enhancement characteristics [non-enhancing (< 10 HU difference), equivocal (10-20 HU), enhancing (> 20 HU)], subjective MRI enhancement, T1 and T2 signal intensity, restricted diffusion, ultrasound (US) echogenicity, and subjective CEUS enhancement.
RESULTS: 148 masses were identified, 122 (82%) of which were malignant and 26 (18%) benign. The three most common tumors were clear cell RCC (n = 47), papillary RCC (n = 35), and ACD-RCC (n = 21). Of the 21 cases of ACD-RCC, 16 had preoperative imaging: CT (15: 6 NECT only, 2 CECT only, 7 combined NECT and CECT), MRI (4), CEUS (5). Ten of these tumors were solid/mostly solid and 6 mixed cystic/solid. On NECT, the average attenuation was 35 HU (range 13-52). Of those with multiphasic CTs, 1 was non-enhancing, 3 were equivocal, and 3 enhanced. All 3 masses imaged with CE-MRI showed enhancement. All 4 tumors evaluated by MRI demonstrated T2 hypointensity and restricted diffusion. All five masses enhanced on CEUS.
CONCLUSION: ACD-RCC subtype was the third most common renal neoplasm in ACKD patients. Our findings found that no single imaging feature is pathognomonic for ACD-RCC. However, ACD-RCCs are typically solid masses with most demonstrating equivocal or mild enhancement on CT. T2 hypointensity and restricted diffusion were the most common MRI features.
引用
- Carnahan, Kunzelman, Kawashima, et al. Acquired cystic disease subtype renal cell carcinoma (ACD-RCC): prevalence and imaging features at a single institution. Abdom Radiol (NY). 2022. PMID: 35674787. doi:10.1007/s00261-022-03566-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。